CereMark Pharma — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

CereMark Pharma is a private, pre-revenue biotech developing precision PET imaging diagnostics for neurodegenerative diseases. Its core asset is F-18 Flornaptitril, a dual tau/amyloid biomarker intended to predict disease progression in patients with Mild Cognitive Impairment, particularly for Alzheimer's and CTE. The company is led by founders with deep expertise in radiopharmaceuticals and brain injury law, and is preparing to initiate clinical trials to advance its drug candidate toward FDA approval.

NeuroscienceNeurodegenerative Diseases

Technology Platform

Novel PET imaging radiopharmaceuticals; lead candidate F-18 Flornaptitril is a small molecule designed to bind both tau protein aggregates and beta-amyloid plaques for in vivo imaging.

Opportunities

The massive and growing population suffering from Alzheimer's and the emerging recognition of CTE create a significant unmet need for early, predictive diagnostics.

A successful dual tau/amyloid tracer could become a standard tool for differential diagnosis and patient stratification, capturing share in both established and novel markets.

Risk Factors

High clinical development risk, unproven financial runway, and intense competition from approved single-pathology tracers and other companies developing next-generation imaging agents.

Commercial success depends on demonstrating clear clinical utility and securing favorable reimbursement.

Competitive Landscape

CereMark competes in the neuroimaging space against large players like Eli Lilly (Amyvid, Tauvid) and GE Healthcare, as well as other biotechs developing novel tau and amyloid tracers. Its key differentiator is the dual-target mechanism, but it faces the challenge of displacing established, single-target standards of care.

More companies in Radiopharmaceuticals →More companies in United States →